Compile Data Set for Download or QSAR
Report error Found 326 Enz. Inhib. hit(s) with Target = 'Receptor-interacting serine/threonine-protein kinase 1 [8-327]'
TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529926(Preparation of 4-(3,3-difluoro-2,2-dimethyl-propan...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529930(1-(3,5-dihydro-2H- 1,4-benzoxazepin- 4-yl)-2,2-dim...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529931(1-(3,5-dihydro-2H- 1,4-benzoxazepin- 4-yl)-3,3-dif...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529932(3,5-dihydro-2H- 1,4-benzoxazepin- 4-yl-[1-(5- fluo...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529933(3,5-dihydro-2H- 1,4-benzoxazepin- 4-yl-[1-(5- fluo...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529937(3,3-difluoro-1-(9- fluoro-2,3- dihydrobenzo[f] [1,...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529938(4-(9-fluoro-3,5- dihydro-2H-1,4- benzoxazepin-4-yl...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529939(2-cyclopropyl-1-(9- fluoro-3,5-dihydro- 2H-1,4- be...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529940(4,4-difluoro-1-(9- fluoro-3,5-dihydro- 2H-1,4- ben...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529942(3,3-difluoro-1-(9- fluoro-3,5-dihydro- 2H-1,4- ben...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529944(3,3-difluoro-1-(6- fluoro-2,3- dihydrobenzo[f] [1,...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529945(3,3-difluoro-2,2- dimethyl-1-(3- methyl-2,3- dihyd...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529946(4-(3,3-difluoro-2,2- dimethyl- propanoyl)-7- fluor...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529947(4-(3,3-difluoro-2,2- dimethyl- propanoyl)-3,5- dih...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529948(4-[1-(5- fluoropyrimidin-2- yl)-4-methyl- piperidi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529949(4-(3-cyano-2,2- dimethyl- propanoyl)-3,5- dihydro-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529950(4-(2-cyclopropyl-2- methyl-propanoyl)- 3,5-dihydro...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529953(4-(3,3-difluoro-2,2- dimethyl- propanoyl)-3,5- dih...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529954(4-(2-cyclopropyl-2- methyl-propanoyl)- 3,5-dihydro...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529956(1-(7-fluoro-2,3,4,5- tetrahydro-1,4- benzoxazepin-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529957(3,3-difluoro-1-(7- fluoro-2,3,4,5- tetrahydro-1,4-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529964(4-[1-(5- fluoropyrimidin-2- yl)-4-methyl- piperidi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529969(4-(3,3,3-trifluoro- 2,2-dimethyl- propanoyl)-3,5- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529971(4-(4,4,4-trifluoro- 2,2-dimethyl- butanoyl)-3,5- d...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529973(4-[1- (difluoromethyl)cyclo- butanecarbonyl]- 3,5-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529975(4-[2,2-dimethyl-3- (trifluoromethoxy) propanoyl]-3...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529976((3R)-4-(3,3- difluoro-2,2- dimethyl- propanoyl)-3-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529978(US11203600, Example 207 | 4-(2,2- dimethylbutanoyl...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529980(4-(2-cyclopropyl- 3,3-difluoro-2- methyl-propanoyl...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529981(4-(2- (difluoromethyl)-2- methylbutanoyl)- 2,3,4,5...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529991(4-[2-methyl-2- (trifluoromethyl) butanoyl]-3,5-dih...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529993(4-[2-methyl-2- (trifluoromethoxy) propanoyl]-3,5- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529998(4-[2-(cyanomethyl)- 2-methyl-butanoyl]- 3,5-dihydr...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM529999((3R)-4-(2,2- dimethylbutanoyl)- 3-methyl-3,5- dihy...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530001((3R)-4-(3-fluoro- 2,2-dimethyl- propanoyl)-3- meth...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530002((3R)-4-(2,2- dimethylpropanoyl)- 3-methyl-3,5- dih...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530008(4-[2-(3,3- difluorocyclobutyl)- 2-methyl- propanoy...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530010((3R)-4-[4-fluoro-1- (5-fluoropyrimidin- 2-yl)piper...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530013(4-(cis-3-(5- fluoropyrimidin-2- yl)-3- azabicyclo[...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530014(4-[2-[1-(5- fluoropyrimidin-2- yl)pyrrolidin-3-yl]...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530020(4-[3,3-difluoro-1- (5-fluoropyrimidin- 2-yl)-4-met...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530021(4-(4-fluoro-1- quinazolin-2-yl- piperidine-4- carb...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530027(4-[4-fluoro-1-(4- methoxypyrimidin- 2-yl)piperidin...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530028((3R)-4-(1-(5- fluoropyrimidin-2- yl)piperidine-4- ...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530029((3R)-4-[1-(5- fluoropyrimidin-2- yl)-4-methoxy- pi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530034(4-(4-fluoro-1- (pyrazolo[1,5- a]pyrimidin-7- yl)pi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530038(4-[4-fluoro-1-(5- fluoro-2-methoxy- pyrimidin-4- y...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530041(4-[1-(4- methoxypyrimidin- 2-yl)piperidine-4- carb...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530042(4-[1-(5-fluoro-4- methoxy-pyrimidin- 2-yl)piperidi...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetReceptor-interacting serine/threonine-protein kinase 1 [8-327](Human)
Denali Therapeutics

US Patent
LigandPNGBDBM530043((3R)-4-(1-(4- methoxypyrimidin- 2-yl)piperidine-4-...)
Affinity DataIC50: 100nMAssay Description:Test compounds were serially diluted in DMSO at 100 fold final concentrations in the assay (1% DMSO final). In each well of a 384-well Plate were dis...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 326 total ) | Next | Last >>
Jump to: